• Hypertension:
    • PO 5-10mg OD or divided BD
    • Max 20mg/day divided BD
    • Decreased efficacy as monotherapy in Black patients, consider combo treatment
  • Risk of cardiovascular mortality or MI in patients with stable CAD:
    • PO 5mg OD *2/52, then increase as tolerated to 10mg/day divided BD
  • Heart failure with reduced ejection fraction:
    • Initially PO 5mg OD to a max of 10-20mg OD
  • Tablet:
    • 5mg
    • 10mg

None remarkable

Angiotensin converting enzyme (ACE) inhibitors

It inhibits angiotensin converting enzyme, interfering with conversion of angiotensin I to angiotensin II and by inhibiting bradykinin metabolism. These actions result in preload and afterload reductions on the heart

  • Cough
  • Hypotension
  • Dizziness
  • Headache
  • Fatigue
  • Elevated BUN/Cr
  • Musculoskeletal pain
  • URI symptoms
  • Hyperuricemia
  • Hypersensitivity to perindopril/other ACE inhibitors
  • History of hereditary or angioedema associated with previous ACE inhibitor treatment
  • Bilateral renal artery stenosis
  • Within 36 hours of switching to or from sacubitril/valsartan (increased risk of angioedema)
  • Pregnancy
  • CrCl <30

WARNING

  • Fetal/neonatal morbidity/mortality may occur when drugs that act directly on the renin-angiotensin system are used in pregnancy
  • Discontinue immediately pregnancy is detected
  • Aliskiren
  • Protein a column
  • Sacubitril/valsartan

                          Drug Status

Availability Prescription only
Pregnancy Not recommended
Breastfeeding Not recommended
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Coversyl 5mg Tablet 30’s Les Laboratoires Harley’s Ltd
Coversyl 10mg Tablet 30’s Les Laboratoires Harley’s Ltd